Chemotherapy of large intestinal carcinoma. Current results and future prospects
| Autor: | Philip S. Schein, John S. Macdonald, Daniel L. Kisner |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Nitrosourea Vincristine education.field_of_study Chemotherapy Colorectal cancer business.industry medicine.medical_treatment Population Combination chemotherapy medicine.disease Surgery chemistry.chemical_compound chemistry Internal medicine medicine Carcinoma education business Adjuvant medicine.drug |
| Zdroj: | Cancer. 36:2418-2420 |
| ISSN: | 1097-0142 0008-543X |
| DOI: | 10.1002/1097-0142(197512)36:6<2418::aid-cncr2820360622>3.0.co;2-m |
| Popis: | Chemotherapy of advanced stages of large bowel cancer has until recently made little progress since the introduction of 5-FU 16 years ago. While survival is improved for patients who respond, 5-FU alone has made little impact on life span of the overall population of patients. Mitomycin-C and the chloroethyl nitrosourea antitumor agents, and in particular methyl-CCNU, have also demonstrated marginal activity in large bowel cancer. Two recently reported controlled clinical trials of combination chemotherapy have demonstrated response rates that are substantially better than those obtained with 5-FU alone; a 43% response rate in colorectal carcinoma has been reported using a combination of 5-FU, BCNU, vincristine, and DTIC, compared to a 25% response with 5-FU as a single agent; a 44% objective response rate with a combination of 5-FU, methyl-CCNU, and vincristine has been reported to be significantly better than 5-FU alone. 5-FU as an adjuvant following surgical resection with curative intent has not prevented tumor relapse; however, it is hoped that future studies employing more effective drug combinations will result in increased number of patients achieving disease free survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text